الفهرس 
List of ContentsOnly 14 pages are availabe for public view
 |  | from | 169 |  |  |
| | | from | 169 | | |
Abstract
Background : Hepatitis C virus (HCV) infection is a major risk factor for liver cirrhosis and hepatocellular carcinoma (HCC), and is a leading cause of liver-related deaths worldwide IGF-1 is an important growth hormone, mediating the anabolic and linear growth promoting effect of pituitary GH protein. The low expression of IGF-1 in CHC patients reflect significant damage to liver parenchyma. Purpose: The aim of this study is to detect the validity of IGF-1 as a predictor for enhancement of the liver functions after using DAAs among HCV cirrhotic patients The aim of this study was Subject and Methods : included 60 patients with chronic hepatitis C liver disease from Hepatology Outpatient Clinics in Mansoura New General Hospital in addition to 60 healthy persons with negative HCV antibodies as control group. Patients received sofosbuvir (400mg), daclatasvir (60mg) and ribavirin (1000-1200 mg\day) according to body weight (less than 75 KG and more than 75 KG body weight, respectively) for 12 weeks. Patients were subjected to careful history taking, clinical examination and standard laboratory assessment. Serum IGF-1 level was assessed for patients before treatment and after 12 weeks from the end of treatment and for once to control group. Assessing the patients according to different scores (Child Pugh – MELD – Fib4 – APRI) was also done. * Results : There was a statistically significance higher median serum IGF-1 level among studied cases after treatment as compared to that before treatment with percentage of improvement was 75% There was a statistically significant decrease in the non-invasive liver assessment by different scoring system (APRI, FIB4 and MELD scores) among studied patients before and after treatment. There was a statistically significant decrease in AST and ALT after treatment as compared with before treatment values.Mean platelets count significantly increase after treatment. Conclusion : The importance of IGF-1 as a potential biomarker for assessment of the improvement of hepatic functions .IGF-1 can be used as noninvasive hepatic evaluation.